Angina Pectoris Drugs Market was valued at US$ 11.28 Bn in 2021, and it is expected to reach US$ 16.02 Bn by 2029, exhibiting a CAGR of 4.49 % during the forecast period 2022-2029.
Angina Pectoris Drugs Market Overview:Angina Pectoris is one type of Chest pain or discomfort due to coronary heart disease. When heart muscles can’t get the blood which it needed that time heart’s arteries get blocked or narrowed which causes uneasiness or chest pain, it also called Angina Pectoris or Ischemia. To know about the Research Methodology :- Request Free Sample Report The report explores the Angina Pectoris Drugs Market's segments (Therapeutic Class, Type, End User). Data has been provided by market participants, and regions (North America, Asia Pacific, Europe, Middle East & Africa, and South America). The MMR market report provides a thorough analysis of the rapid advances that are currently taking place across all industry sectors. Facts and figures, illustrations, and presentations are used to provide key data analysis for the historical period from 2017 to 2021. The report investigates the Angina Pectoris Drugs Market’s drivers, limitations, prospects, and barriers. This MMR report includes investor recommendations based on a thorough examination of the Angina Pectoris Drugs Market's contemporary competitive scenario.
Angina Pectoris Drugs Market Dynamics:Angina pectoris is a heart disorder marked by a narrowing of the coronary arteries, resulting in a reduction in blood flow to the heart. Squeezing, heaviness, tightness, or pain in the chest are some of the symptoms. Chest pain, uneasiness, dizziness, weariness, nausea, shortness of breath, and sweating were all symptoms of angina pectoris. Antianginal medicines are medications that are used to treat angina pectoris. Angina pectoris attacks can be prevented, aborted, or terminated with the use of these medications. Antianginal medicines reduce oxygen demand, improve oxygen transport to the heart, block calcium channels, and prevent platelet aggregation. Because of the increased focus on treating medical problems that affect the older population, the global market for angina pectoris medications has seen an increase in demand. The development of a unified sector for healthcare diagnostics and treatment has aided market expansion significantly. Reduced blood supply to the heart causes angina pectoris, which is a type of chest pain. Angina pectoris occurs more frequently in the elderly population. For the treatment of angina pectoris, a variety of medications have been produced, which is a crucial consideration in terms of market growth. These medications aid in the regulation of blood flow to the heart, which compensates for a lack of blood supply. The global angina pectoris market's demand and supply forces have improved significantly during the last decade. The field of geriatric diagnosis and treatment has seen significant advancements, which has assisted market growth. The global angina pectoris market is predicted to increase at a steady rate in the coming years. The creation of medical growth indices has had a direct impact on the worldwide angina pectoris market's growth. Drivers: The growing older population has contributed significantly to the growth of the worldwide angina pectoris medicines market. Although adults over the age of 60 are more susceptible to angina pectoris, this condition can affect persons of all ages. As a result, demand for angina pectoris medications in the global market has come from a variety of segments and age groups. The significant prevalence of cardiovascular-related ailments worldwide is due to lifestyle diseases and their chronic nature. According to the Nesia Foundation Hospital, around 14.2 million people aged 30-69 years die prematurely as a result of lifestyle conditions such as diabetes, arteriosclerosis, excessive cholesterol, stroke, nephritis, cancer, and other diseases. Women exhibit more unusual indicators of heart attack than males, according to multiple published studies on lifestyle-related disorders. Furthermore, there is a greater risk of misdiagnosis or delayed diagnosis, which reduces the likelihood of receiving immediate life-saving therapy such as primary angioplasty and stents. The rising burden of lifestyle diseases has a direct impact on the socioeconomic elements of nations around the world, necessitating immediate action to manage them. The increase in the patient population suffering from cardiac illnesses such as coronary heart disease is one of the primary driving reasons for market growth. According to the Globe Health Organization, ischemic heart disease was the top cause of mortality in the world in December 2020, accounting for 16 percent of all deaths. Stroke and chronic obstructive pulmonary disease (COPD) are the second and third leading causes of death, respectively accounting for around 12% and 8% of all deaths. Over the last decade, there have been significant advancements in the field of medication creation. In recent years, this aspect has directly contributed to the expansion of the worldwide angina pectoris medications market. The medical community's search for new treatment options for cardiovascular disorders has also boosted market expansion. Restrain: Some of the reasons that may restrain the market's growth in the next years include the increasing usage of less invasive operations and the adverse effects associated with specific drug classes. Opportunities: The pharmaceutical sector is intimately tied to the global market for angina pectoris medications, and this has played a significant role in market expansion. The top suppliers in the worldwide angina pectoris medications market have been on a mission to increase their customer base. Some vendors have made significant investments in innovative technology research and development. Challenges: The high cost of therapy, as well as government rules and policies regarding drug patents, may limit market expansion in the foreseeable future. Covid19 Impact: Pain was a common symptom among the patients, and some of them had chest pain that resembled angina pectoris. Patients with angina pectoris are particularly sensitive to the new virus's attacks. When infected, those with ischemic heart disease and heart failure (HF) have a higher risk of morbidity and mortality. When it comes to senior persons with diabetes mellitus, the aforementioned dangers are amplified. As a result, if these patients come into touch with persons infected with COVID-19, the international suggestion is that they stay in lockdown and quarantine for as long as possible. As a result, this aspect will propel the market forward during the forecast period. Due to lockdown restrictions, a drop in the frequency of patient hospital visits, and supply chain disruption, the COVID-19 had a significant impact on the angina pectoris market during the early pandemic. For example, according to an article published in Pain Medicine in November 2020 titled "COVID-19 Pandemic and Angina Pectoris: what if the Pain Pathway Is Pharmaceutically Modulated?" the number of cardiovascular patients visiting emergency rooms has dropped in the case of COVID-19. Patients have ascribed the discrepancy to a COVID-19 phobia, which means that persons with angina pectoris avoid attending to emergency rooms for fear of contracting the virus. In the early stages of the outbreak, such instances harmed the market's growth. With the growing consequences of heart disease among COVID-19 patients, demand for angina pectoris medications is projected to rise. For example, according to a study titled "Long COVID-19 and microvascular disease related angina" published in Sociedad Espaola de Cardiologa in November 2021, researchers discovered that 27 percent of patients evaluated in a long COVID-19 unit had chest pain, some of which was suggestive of angina, after meticulous evaluation and exclusion of other illnesses. The experiment enrolled a total of 186 patients, 51 (27%) of whom reported continuing chest pain after being assessed in the extended COVID-19 unit. As a result of these investigations, the need for medications to treat angina pectoris in COVID-19 patients was highlighted, resulting in an increase in drug demand. As a result, the rising number of COVID-19 patients suffering from cardiological problems is expected to propel the market forward throughout the forecast period.
Angina Pectoris Drugs Market Segment Analysis:Based on Therapeutic Class, beta Blockers is dominating the market with highest CAGR during the forecast period. Beta-blockers function by blocking the effects of adrenaline on the heart, decreasing the heart rate and diminishing the force with which the heart muscle contracts. Beta-blockers are considered first-line therapy in patients with stable angina caused by CAD. The segment's rise is mostly due to an increase in the target population and a growing number of strategic advancements among market competitors aimed at improving beta-blocker drug commercial availability. Calcium Channel Blockers hold the second-largest market share. Calcium channel blockers work by stopping calcium from entering the cells of your heart and arteries, lowering blood pressure. The heart and arteries contract more forcefully when calcium is present. Calcium channel blockers relax and widen blood arteries by inhibiting calcium. Some calcium channel blockers also slow the heart rate, which helps to lower blood pressure, relieve chest pain (angina), and regulate an irregular heartbeat. Based on the End User: The market for angina pectoris medications is dominated by hospital pharmacies. This is mostly due to an increase in the number of patients with illnesses that require treatment in hospitals with modern infrastructure and suitable amenities. Furthermore, the expanding number of hospitals, as well as sufficient reimbursement rules, are both contributing to the segment's growth.
Angina Pectoris Drugs Market Regional Insights:The North America region dominated the market with highest share in 2021. The North America region is expected to witness significant growth at a CAGR of xx% through the forecast period. The global Angina Pectoris medicines market is dominated by the North American region, which will account for the biggest market share in 2022. Its substantial proportion is due to rising therapeutic adoption and the presence of important producers in the United States. Angina is the most prevalent sign of ischemic heart disease, which is a leading cause of death and disability globally. Angina affects approximately 9 million people in the United States, and its treatment can be difficult. Furthermore, the market is being fuelled by the rising incidence of heart illnesses as a result of sedentary lifestyles and positive regulatory initiatives. Melinta Therapeutics was granted the rights to TOPROL-XL (metoprolol succinate) in the US by New American Therapeutics. TOPROL-XL is a cardio-selective beta-blocker approved by the FDA for the treatment of hypertension alone or in collation with other antihypertensives, as well as the long-term therapy of angina pectoris and the treatment of stable, symptomatic heart failure due to certain causes. As a result of these advancements, the segment's growth will be boosted in the near future. Because of its established healthcare infrastructure, greater therapeutic use, and the presence of important producers in the United States, North America dominates the angina pectoris pharmaceuticals market, accounting for a large proportion. In the North American region, ischemic heart disease is a leading cause of death and disability, with angina being the most frequent symptom. According to data published in February 2022 by the National Center for Chronic Disease Prevention and Health Promotion's Division for Heart Disease and Stroke Prevention, the most common kind of heart disease, ischemic heart disease, killed 360,900 lives in 2019. About 18.2 million people aged 20 and up suffer from coronary artery disease. Between 2021 and 2028, the Asia Pacific Angina Pectoris Drugs Market is expected to grow significantly. Companies are working on expanding their product portfolios, diversifying their business operations, lowering costs, increasing customer contentment, and improving Angina Pectoris Drugs reliability in Asia Pacific, where commercial prospects are promising. Due to the removal of price limitations on all drug categories, the continuing Healthy China 2021 healthcare improvement, and supportive 12th Five-Year Plan initiatives that prioritize biotechnology as a key development industry, China presents a great opportunity for market expansion. Furthermore, the region's expansion is likely to be fuelled by the presence of a big target population and significant unmet clinical needs. The objective of the report is to present a comprehensive analysis of the Angina Pectoris Drugs Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also help in understanding the Angina Pectoris Drugs Market dynamic, structure by analyzing the market segments and projecting the Angina Pectoris Drugs Market size. Clear representation of competitive analysis of key players by Vehicle type, price, financial position, product portfolio, growth strategies, and regional presence in the Angina Pectoris Drugs Market make the report investor’s guide.
Angina Pectoris Drugs Market Scope: Inquire before buying
Global Angina Pectoris Drugs Market Report Coverage Details Base Year: 2021 Forecast Period: 2022-2029 Historical Data: 2017 to 2021 Market Size in 2021: US $ 11.28 Bn. Forecast Period 2022 to 2029 CAGR: 4.49% Market Size in 2029: US $ 16.02Bn. Segments Covered: by Therapeutic Class • Nitrates • Beta Blockers • Calcium Channel Blockers • Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors) • Anti-Platelets • Others by Type • Stable Angina • Unstable Angina • Prinzmetal’s Angina by End User • Hospitals • Special Clinic • Others
Angina Pectoris Drugs Market by Region• North America • Europe • Asia Pacific • South America • Middle East and Africa
Angina Pectoris Drugs Market Key Players• Sanofi • Pfizer • Otsuka Pharmaceutical Co., Ltd. • Novartis AG • Merck & Co., Inc. • Gilead Sciences, Inc. • Amgen Inc. • Eli Lilly and Company • GlaxoSmithKline • Axus Cardium Pharmaceuticals • LegoChem Biosciences • Lee’s Pharmaceutical Holdings • Milestone Pharmaceuticals • Juventas Therapeutics • ViroMed • Kuhnil Pharmaceutical • Johnson & Johnson • Bristol-Myers Squibb Company • Abbott • Bayer AG Frequently Asked Questions: 1] What segments are covered in the Global Angina Pectoris Drugs Market report? Ans. The segments covered in the Angina Pectoris Drugs Market report are based on Therapeutic Class, Type, End User. 2] Which region is expected to hold the highest share in the Global Angina Pectoris Drugs Market? Ans. North America region is expected to hold the highest share in the Angina Pectoris Drugs Market. 3] What is the market size of the Global Angina Pectoris Drugs Market by 2029? Ans. The market size of the Angina Pectoris Drugs Market by 2029 is expected to reach US$ 16.02 Bn. 4] What is the forecast period for the Global Angina Pectoris Drugs Market? Ans. The forecast period for the Angina Pectoris Drugs Market is 2022-2029. 5] What was the market size of the Global Angina Pectoris Drugs Market in 2021? Ans. The market size of the Angina Pectoris Drugs Market in 2021 was valued at US$ 11.28 Bn.
1. Angina Pectoris Drugs Market: Research Methodology 2. Angina Pectoris Drugs Market: Executive Summary 2.1. Market Overview and Definitions 2.1.1. Introduction to Angina Pectoris Drugs Market 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Angina Pectoris Drugs Market: Competitive Analysis 3.1. MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2. Consolidation in the Market 3.2.1 M&A by region 3.3. Key Developments by Companies 3.4. Market Drivers 3.5. Market Restraints 3.6. Market Opportunities 3.7. Market Challenges 3.8. Market Dynamics 3.9. PORTERS Five Forces Analysis 3.10. PESTLE 3.11. Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • South America 3.12. COVID-19 Impact 4. Angina Pectoris Drugs Market Segmentation 4.1. Angina Pectoris Drugs Market, By Therapeutic Class (2021-2029) • Beta Blockers • Calcium Channel Blockers • Nitrates • Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors) • Anti-Platelets • Others 4.2. Angina Pectoris Drugs Market, By Type (2021-2029) • Stable Angina • Unstable Angina • Prinzmetal’s Angina 4.3. Angina Pectoris Drugs Market, By End-User (2021-2029) • Hospitals • Specialty Clinics • Others 5. North America Angina Pectoris Drugs Market (2021-2029) 5.1. North America Angina Pectoris Drugs Market, By Therapeutic Class (2021-2029) • Beta Blockers • Calcium Channel Blockers • Nitrates • Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors) • Anti-Platelets • Others 5.2. North America Angina Pectoris Drugs Market, By Type (2021-2029) • Stable Angina • Unstable Angina • Prinzmetal’s Angina 5.3. North America Angina Pectoris Drugs Market, By End-User (2021-2029) • Hospitals • Specialty Clinics • Others 5.4. North America Angina Pectoris Drugs Market, by Country (2021-2029) • United States • Canada • Mexico 6. European Angina Pectoris Drugs Market (2021-2029) 6.1. European Angina Pectoris Drugs Market, By Therapeutic Class (2021-2029) 6.2. European Angina Pectoris Drugs Market, By Type (2021-2029) 6.3. European Angina Pectoris Drugs Market, By End-User (2021-2029) 6.4. European Angina Pectoris Drugs Market, by Country (2021-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Angina Pectoris Drugs Market (2021-2029) 7.1. Asia Pacific Angina Pectoris Drugs Market, By Therapeutic Class (2021-2029) 7.2. Asia Pacific Angina Pectoris Drugs Market, By Type (2021-2029) 7.3. Asia Pacific Angina Pectoris Drugs Market, By End-User (2021-2029) 7.4. Asia Pacific Angina Pectoris Drugs Market, by Country (2021-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Angina Pectoris Drugs Market (2021-2029) 8.1. Middle East and Africa Angina Pectoris Drugs Market, By Therapeutic Class (2021-2029) 8.2. Middle East and Africa Angina Pectoris Drugs Market, By Type (2021-2029) 8.3. Middle East and Africa Angina Pectoris Drugs Market, By End-User (2021-2029) 8.4. Middle East and Africa Angina Pectoris Drugs Market, by Country (2021-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Angina Pectoris Drugs Market (2021-2029) 9.1. South America Angina Pectoris Drugs Market, By Therapeutic Class (2021-2029) 9.2. South America Angina Pectoris Drugs Market, By Type (2021-2029) 9.3. South America Angina Pectoris Drugs Market, By End-User (2021-2029) 9.4. South America Angina Pectoris Drugs Market, by Country (2021-2029) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1. Sanofi 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2 Pfizer 10.3 Otsuka Pharmaceutical Co., Ltd. 10.4 Novartis AG 10.5 Merck & Co., Inc. 10.6 Gilead Sciences, Inc. 10.7 Amgen Inc. 10.8 Eli Lilly and Company 10.9GlaxoSmithKline 10.10Axus Cardium Pharmaceuticals 10.11 LegoChem Biosciences 10.12 Lee’s Pharmaceutical Holdings 10.13 Milestone Pharmaceuticals 10.14 Juventas Therapeutics 10.15 ViroMed 10.16 Kuhnil Pharmaceutical 10.17 Johnson & Johnson 10.18 Bristol-Myers Squibb Company 10.19 Abbott 10.20 Bayer AG